Physician profile
Jerome Thomas
NPI 1225133689
$182,301.01
in general payments reported to CMS, 2019-2025
35 companies · $58K in 2025
The $58K reported for 2025 was more than what 94% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,762 · 2020: $9,632 · 2021: $11K · 2022: $26K · 2023: $21K · 2024: $48K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $70K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $14K · Travel and Lodging: $11K · Education: $38.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $69,618.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,414.00 |
| Food and Beverage | $14,275.05 |
| Travel and Lodging | $11,363.32 |
| Education | $38.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $140,678.58 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Actelion Pharmaceuticals US, INC. | $22,267.34 | 2019-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $5,130.00 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,188.01 | 2024-2025 | Jardiance |
| Abiomed | $3,104.26 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $1,240.87 | 2019-2024 | |
| Lilly USA, LLC | $1,040.00 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $916.12 | 2020-2025 | Brilinta, Wainua, Farxiga |
| Pfizer INC. | $462.78 | 2020-2025 | |
| Impulse Dynamics (USA) INC. | $413.98 | 2022-2025 | Optimizer, Optimizer |
| Cvrx, INC. | $379.13 | 2022-2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $246.65 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $234.67 | 2019 | |
| Boston Scientific Corporation | $226.30 | 2019-2022 | |
| Atricure, INC. | $225.86 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $202.02 | 2021-2025 | Tyvaso, Tyvaso |
| Endotronix, INC. | $185.70 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $177.12 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $169.26 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $137.29 | 2021-2024 | Corevalve Evolut R |
| Merck Sharp & Dohme LLC | $128.50 | 2021-2025 | Verquvo, Winrevair |
| Alnylam Pharmaceuticals INC. | $122.48 | 2020-2025 | Amvuttra, Onpattro |
| Masimo Corporation | $88.94 | 2019 | |
| Heartflow, INC. | $64.94 | 2025 | |
| Inspire Medical Systems, INC. | $42.03 | 2025 | Inspire |
| Lexicon Pharmaceuticals, INC. | $34.79 | 2023 | Inpefa |
| Janssen Pharmaceuticals, INC | $34.77 | 2019-2020 | |
| Scpharmaceuticals INC. | $30.82 | 2023-2024 | |
| Genzyme Corporation | $23.98 | 2025 | |
| Novo Nordisk INC | $22.19 | 2025 | Ozempic |
| Vital Connect, INC | $18.78 | 2023 | Vitalpatch Rtm |
| Glaxosmithkline, LLC. | $17.40 | 2025 | Shingrix |
| Arbor Pharmaceuticals, INC. | $16.62 | 2019 | |
| Chiesi USA, INC. | $14.85 | 2021 | |
| Amgen INC. | $13.98 | 2023 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.